

Product Information

CompoZr® Disease Model Cell Lines MCF10A Cells PTEN -/- PIK3CA H1047R +/-

Catalog Number **CLLS1199**

Storage Temperature -196 °C (liquid nitrogen)

Product Description

CompoZr zinc finger nuclease (ZFN) technology is a fast and reliable way to manipulate the genome in a targeted fashion. ZFNs are synthetic proteins engineered to bind DNA at a sequence-specific location and create a double strand break (www.compozrzfn.com). The cell's natural machinery repairs the break in one of two ways: non-homologous end joining (NHEJ) or homologous recombination.

In order to prepare the PTEN knockout/PIK3CA-H1047R SNP, a foundation line carrying the PTEN gene knocked out was generated. Both alleles coding for PTEN were knocked out, relying on NHEJ and introducing a 19 base pair deletion in one allele and a 2 base pair deletion in the second allele (see Figure 1). Using the PTEN -/- line and a different ZFN pair, a donor oligonucleotide with a single nucleotide change was included when cells were treated with the ZFN nuclease targeting the PIK3CA site. As a result of homologous recombination in the presence of the donor oligo, this SNP was introduced in one allele (see Figure 2). Single cell clones were isolated and followed for more than twenty passages to establish stable cell lines.

While the targeted genes in this cell line are diploid, ZFN-mediated gene knockout technology is not limited to diploid targets, allowing the researcher to pursue many of the polyploid cell lines often characteristic of cancer. Modified cell lines provide the basis for the development of various assays for compound screening.

The phosphatidylinositol 3-kinase (PI3K) pathway has been described as the "...most frequently mutated pathway in breast cancer...".¹ The H1047R mutation in the PIK3CA gene is a known proto-oncogene and has been shown to be associated with a number of human cancers including breast cancer.² Additionally, loss of PTEN function coupled with the H1047R mutation in PIK3CA has been implicated in further promoting the oncogenic state.³⁻⁵

Components

MCF10A mutant cell line with PTEN -/- 1 vial
 PIK3CA H1047R +/- SNP insertion
 Catalog No. CLL1199

Parental mammary epithelial cell line 1 vial
 (ATCC® Catalog No. CRL-10317™)
 Catalog No. CLL1040

1 vial of MCF10A cells contains $\sim 2 \times 10^6$ cells.

The cryoprotectant medium used is Cell Freezing Medium-DMSO 1x, Catalog No. C6164.

Figure 1.

Creation of PTEN Knockout in MCF10A Cells

Site-specific deletion at the PTEN Locus in MCF10A cell line

Allele 1 – del 19

TTTAAATACCTGTTAAGTTTGTATGCAACATTTCTA
 AAGTTACCTACTTGTAAATTAATAAATTCAAGAGTTTT
 TTTTCTTATTCTGAGGTTATCTTTTACCACAGTTG
 CACAATATCCTTTTGAAGACCATAACCCACCACAGC
 TAGAACCTTATCAAAACCCTTTgtGAAGATCTTGACCAA
 TGGCTAAGTGAAGATGACAATCATGTTGCAGCAATT
 CACTGTAAAGCTGGAAAGGGACGAACTGGTGTAAAT
 GATATGTGCATATTTATTACATCGGGGCAAATTTT
 AAAGGCACAAGAGGCCCTAGATTCTA

Allele 2 – del 2

TTTAAATACCTGTTAAGTTTGTATGCAACATTTCTA
 AAGTTACCTACTTGTAAATTAATAAATTCAAGAGTTTT
 TTTTCTTATTCTGAGGTTATCTTTTACCACAGTTG
 CACAATATCCTTTTGAAGACCATAACCCACCACAGC
 TAGAACCTTATCAAAACCCTTTgtGAAGATCTTGACCAA
 TGGCTAAGTGAAGATGACAATCATGTTGCAGCAATT
 CACTGTAAAGCTGGAAAGGGACGAACTGGTGTAAAT
 GATATGTGCATATTTATTACATCGGGGCAAATTTT
 AAAGGCACAAGAGGCCCTAGATTCTA

Schematic of the genomic sequence at the target region (exon 11) recognized by the ZFN pair, the resulting deletion, and the CEL-I primer sequences

Genotype: del 19/del 2 (heterozygous)

CEL-I Primers - **Bolded and underlined**

ZFN binding site - **UPPER CASE, BOLDED RED**

ZFN cut site - **lower case red**

Deletion – **yellow highlighted, red**

Figure 2.

Creation of PIK3CA heterozygous H1047A Single Nucleotide Knock-In in MCF10A PTEN -/- Cells

Site-specific single nucleotide change at the PIK3CA Locus in MCF10A cell line

Allele 1 – SNP H1047R integrated

CATTGCTCCAACTGACCAAACTGTTCTTATTACT
TATAGGTTTCAGGAGATGTGTTACAAGGCTTATCTA
GCTATTCGACAGCATGCCAATCTCTTCATAAATCTT
TTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTA
CAATCTTTTGATGACATTGCATACATTGCAAAG**ACC**
CTAGCCTTAgataaa**ACTGAGCAAGAGGCT**TTGGAG
TATTTTCATGAAACAAATGAATGATGCA**CCT**CATGGT
GGCTGGACAACAAAAATGGATTGGATCTTCCACAC
AATTAAACAGCATGCATTGAACTGAAAAGATAACTG
AGAAAATGA**AAGCTCACTCTGGATTCCACA**

Allele 2 – wild type

CATTGCTCCAACTGACCAAACTGTTCTTATTACT
TATAGGTTTCAGGAGATGTGTTACAAGGCTTATCTA
GCTATTCGACAGCATGCCAATCTCTTCATAAATCTT
TTCTCAATGATGCTTGGCTCTGGAATGCCAGAACTA
CAATCTTTTGATGACATTGCATACATTGCAAAG**ACC**
CTAGCCTTAgataaa**ACTGAGCAAGAGGCT**TTGGAG
TATTTTCATGAAACAAATGAATGATGCA**CAT**CATGGT
GGCTGGACAACAAAAATGGATTGGATCTTCCACAC
AATTAAACAGCATGCATTGAACTGAAAAGATAACTG
AGAAAATGA**AAGCTCACTCTGGATTCCACA**

Schematic of the genomic sequence at the target region (exon 20) recognized by the ZFN pair, the resulting heterozygous nucleotide change, and the CEL-I primer sequences

Genotype: H1047R (a.k.a A3140G)(heterozygous)

CEL-I Primers - **Bolded and underlined**

ZFN binding site - **UPPER CASE, BOLDED RED**

ZFN cut site - **lower case red**

Nucleotide change - **UPPER CASE, BOLDED BLUE**
(change from A, wild type, to G)

Codon change - **green highlighted**
(change from CAT, wild type, to CGT)

Cell Line Description

Organism: *Homo sapiens* (human)

Tissue: mammary gland; breast

Age: 36 years

Gender: Female

Ethnicity: Caucasian

Morphology: Epithelial

Growth properties: Adherent

DNA profile

Short Tandem Repeat (STR) analysis:

Amelogenin: X

CSF1PO: 10,12

D13S317: 8,9

D16S539: 11,12

D5S818: 10,13

D7S820: 10,11

THO1: 8,9.3

TPOX: 9,11

vWA: 15,17

Parental Cell Line: ATCC Catalog No. CRL-10317

Note: Please see CRL-10317 product datasheet from ATCC for additional information about the origin of these cell lines. Cytogenetic information is based on initial seed stock at Sigma Life Science. Cytogenetic instability has been reported in the literature for some cell lines.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Biosafety Level: 1

This cell line is not known to harbor an agent known to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. The parental cell line, MCF10A, was obtained from ATCC. All animal products used in the preparation of the knockout line and maintenance of both, parental and knockout clone, have been screened negative by 9CFR for adventitious

viral agents. Cell lines derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. Appropriate safety procedures are recommended to be used when handling all cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures have been published.⁶⁻⁹

Storage/Stability

Upon receiving a shipment of frozen cells it is important the end user gives the shipment attention without delay. To ensure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C . Storage at -70°C will result in loss of viability.

Precaution: It is recommended that protective gloves and clothing always be used, and a full face mask always be worn when handling frozen vials. It is **important to note that some vials leak when submersed in liquid nitrogen** and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to the gas phase may result in the rapid expansion of the vessel, potentially blowing off its cap with dangerous force creating flying debris.

At the time a cell line is ordered, end users should also consider the culture conditions for the new cell line and make sure the appropriate medium will be available when the cells arrive.

Preparation Instructions

Complete Medium

Dulbecco's Modified Eagle's Medium (DMEM)/Ham's Nutrient Mixture F12 (1:1) with 2.5 mM L-glutamine, 5% horse serum, 10 $\mu\text{g/mL}$ human insulin, 0.5 $\mu\text{g/mL}$ hydrocortisone, 10 ng/mL EGF, and 100 ng/mL cholera toxin. This medium is formulated for use with a 5% CO_2 in air atmosphere.

Medium Components:

DMEM/F12, Catalog No. 51448C

Cholera Toxin from *Vibrio cholerae*, Catalog No. C8052

Epidermal Growth Factor, Catalog No. E9644

Horse Serum, Catalog No. H1270

Hydrocortisone Solution, 50 μM . Catalog No. H6909

Insulin Solution, Catalog No. I9278

To make the complete growth medium combine the following:

1. 1 liter of DMEM/F12
2. 108 μL of Cholera toxin solution (1 mg/mL), prepared by dissolving Catalog Number C8052 in sterile water. Store solution at $2-8^{\circ}\text{C}$.
3. 10.8 μL of EGF solution (1 mg/mL), prepared by dissolving Catalog Number E9644 in 10 mM acetic acid, followed by 0.2 μm filtration. Store the solution in aliquots at -20°C .
4. 50 mL of horse serum
5. 29 mL of Hydrocortisone Solution, 50 μM
6. 1.08 mL of Insulin Solution

Procedure

Thawing of Frozen Cells

1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (~ 2 minutes).
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
3. Transfer the vial contents to a centrifuge tube containing 9.0 mL of Complete Medium and spin at $\sim 125 \times g$ for 5–7 minutes.
4. Resuspend cell pellet with the Complete Medium and dispense into a 25 cm^2 culture flask. It is recommended to begin the culture in a 25 cm^2 flask as the initial adaptation and expansion of the cells is more rapid in a denser environment. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested, prior to the addition of the vial contents, the culture vessel containing the Complete Medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0–7.6) and temperature (37°C).
5. Incubate the culture at 37°C in a suitable incubator. A 5% CO_2 in air atmosphere is recommended for the Complete Medium.

Subculturing Procedure

Volumes used in this procedure are for a 75 cm² flask; proportionally reduce or increase volume of dissociation medium for culture vessels of other sizes.

1. Cells prefer to grow in a more dense environment. Allow cells to become 70-90% confluent before attempting to pass. Be aware that this line tends to form "clumps" of cells that are free in the media or loosely attached. It is not uncommon to be able to harvest the culture supernatant and pellet cells sufficient to allow passage. Additionally, this cell line tends to convert the media, i.e. lower the pH, more quickly than the parent cells line. Media may have to be change more often.
2. Remove and the culture medium. It cells present in the culture medium can be recovered by gentle pelleting and resuspension in fresh media.
3. Briefly rinse the cell layer with Accutase (Catalog No. A6964). This cell dissociation solution does not contain mammalian or bacterial-derived products and has been observed to be gentler regarding the dissociation/detachment of this cell line.
4. Add 2.0–3.0 mL of Accutase solution to the flask and incubate at 37 °C for 3-5 minutes (examine the flask every 2 minutes in order to minimize exposure). After the first two minutes, gently agitate cells by hitting side of flask with palm of hand. Examine to determine if cells have released.
5. When cells are detached, add 6.0–8.0 mL of Complete Medium and aspirate cells by gentle pipetting.
6. Gently pellet the cells, remove the supernatant, and resuspend to 6.0–8.0 mL with prewarmed (37 °C) Complete Medium.
7. Add appropriate aliquots of the cell suspension into new culture vessels. Subcultivation Ratio: 1:1.
8. Incubate cultures at 37 °C.

Note: MCF10A parental cells require longer time for digestion/cell release than what is typical. However, it is recommended when passing cells to check every 5 minutes in order to minimize exposure time to Accutase. More information on enzymatic dissociation and subculturing of cell lines is available in the literature.¹⁰

References

1. Miller, T.W., et al. Mutations in the phosphatidylinositol 3-kinase pathway: role of tumor progression and therapeutic implications in breast cancer. *Breast Cancer Res.*, **13**(6), 224 (2011).
 2. Lee, J.W., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene*, **24**(8), 1477-80 (2005).
 3. Castaneda, C.A., et al. The phosphatidyl inositol 3-kinase / AKT signaling pathway in breast cancer. *Cancer Metastasis Rev.*, **29**(4), 751-9 (2010).
 4. Nicolantonio, F. et al., Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. *J. Clin. Invest.*, **120**, 2858-66 (2010).
 5. Mohseni, M. and B. H. Park. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. *J. Clin. Invest.*, **120**(8), 2655-2658 (2010).
 6. Centers for Disease Control (1999), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 4th Edition U.S. Government Printing Office Washington D.C. The entire text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm
 7. Fleming, D.O. et al., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.
 8. Hay, R.J. et al., eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.
 9. Caputo, J.L., Biosafety procedures in cell culture. *J. Tissue Culture Methods*, **11**, 223-227 (1988).
 10. Freshney, R.I., Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by, 3rd edition, published by Alan R. Liss, (NY, NY: 1994).
- Additional product and technical information can be obtained from the catalog references and the Sigma Life Science Website www.sigma.com/biocells
 - Please see the Label License Agreement (LLA) for further details regarding the use of this product. The LLA is available on our Web site at <http://www.sigmaaldrich.com/content/sigma-aldrich/areas-of-interest/life-science/zinc-finger-nuclease-technology/zfn-license-agreement.html>
 - These cells are distributed for research purposes only. Sigma Life Science requires that individuals contemplating commercial use of any cell line first contact us to negotiate an agreement. Third party distribution of this cell line is prohibited.

CompoZr is a registered trademark of Sigma-Aldrich Co. LLC.
ATCC is a registered trademark of American Type Culture Collection.
CRL-10317 is a trademark of American Type Culture Collection.

GW,ADM,PHC 07/12-1